Serving hundreds of leading biopharmaceutical companies globally:

Generated: February 20, 2019

DrugPatentWatch Database Preview

Drug Sales Trends for INSULIN NOVOLIN NPH/REG

« Back to Dashboard

Payment Methods and Pharmacy Types for INSULIN NOVOLIN NPH/REG (2016)

Revenues by Pharmacy Type

Chart
Table

Pharmacy Type	Revenues
MAIL-ORDER	$2,325,770
INSIDE ANOTHER STORE	$157,776,585
[disabled in preview]	$323,532,635
This preview shows a limited data set Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Chart
Table

Pharmacy Type	Units
MAIL-ORDER	121,322
INSIDE ANOTHER STORE	583,863
[disabled in preview]	1,084,838
This preview shows a limited data set Subscribe for full access, or try a Trial

Revenues by Payment Method

Chart
Table

Payment Method	Revenues
MEDICAID	$7,155,992
MEDICARE	$229,895,004
[disabled in preview]	$246,607,945
This preview shows a limited data set Subscribe for full access, or try a Trial

Drug Sales Revenue Trends for INSULIN NOVOLIN NPH/REG

Drug Units Sold Trends for INSULIN NOVOLIN NPH/REG

Annual Sales Revenues and Units Sold for INSULIN NOVOLIN NPH/REG

These sales figures are drawn from a US national survey of drug expenditures

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Drug Name	Revenues (USD)	Units	Year
INSULIN NOVOLIN NPH/REG	➤ Try a Free Trial	➤ Try a Free Trial	2016
INSULIN NOVOLIN NPH/REG	➤ Try a Free Trial	➤ Try a Free Trial	2015
INSULIN NOVOLIN NPH/REG	➤ Try a Free Trial	➤ Try a Free Trial	2014
INSULIN NOVOLIN NPH/REG	➤ Try a Free Trial	➤ Try a Free Trial	2013
INSULIN NOVOLIN NPH/REG	➤ Try a Free Trial	➤ Try a Free Trial	2012
INSULIN NOVOLIN NPH/REG	➤ Try a Free Trial	➤ Try a Free Trial	2011
INSULIN NOVOLIN NPH/REG	➤ Try a Free Trial	➤ Try a Free Trial	2010
Drug Name	Revenues (USD)	Units	Year

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt

Queensland Health

Harvard Business School

Boehringer Ingelheim

UBS

Colorcon

Covington

Cipla

Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.